BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 26, 2010
 |  BioCentury  |  Emerging Company Profile

Savara: Deep Focus on Lungs

Savara inhalation technology aims to solve poor penetration of drugs into lungs

The objective of most inhalation delivery technologies is to deliver therapeutic directly to the target organ while avoiding systemic issues. Savara Inc. believes its nanocluster dry powder inhalation technology will allow the biotech to deliver more active drug to the deep lung, which the company believes will translate into more efficient delivery and new indications for inhaled therapeutics.

According to CEO Robert Neville, current dry powder delivery technologies rely on bulky carrier molecules like lactose, because at less than 1 micron in diameter, most drugs are too small to stay in the airway without being exhaled.

Adding a carrier results in particles > 5 microns in size, which keeps the drug from being expelled but also slows its flight, causing it to stop short of the distal regions of the lung.

The percentage of emitted dose that is respirable is known as the fine particle fraction (FPF) that makes its way to...

Read the full 742 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >